Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 8;7:11762. doi: 10.1038/ncomms11762

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) Representative images of whole-body imaging for PDSC5 tumour cell-fibroblast co-injections day 9 post injection. Scale for photon flux is shown to the right of the image. (b) Tumour growth following non-senescent (Non-Sen) or senescent (Sen) subcutaneous co-injections with PDSC5 tumour cells. Live imaging analysis of day 9 growth is represented as MPF (photons per second)+s.e.m. * indicates P value <0.05 by Student's t-test. n=8. Data shown here is derived from the same experiment shown in Fig. 6b, thus Sen mice received IgG control antibody. (c) Tumour growth following Non-Sen or Sen subcutaneous co-injections with MK16-Ras tumour cells. Caliper measurements were performed on day 26 following injection. * indicates P value <0.05 by Student's t-test. Data are presented as mean tumour area (mm²)+s.e.m. n=8–9. (d) IF CD31 (red) staining Sen versus Non-Sen subcutaneous PDSC5 tumour co-injections. Scale bar, 100 μM. Representative images. (e) Quantification of CD31 IF staining shown in f. ns is not significant by Student's t-test. Data are presented as the MFI+s.e.m. per × 20 FOV. n=7–8. FOV, field of view. MPF, mean photon flux. (f) Tumour growth following subcutaneous co-injections with PDSC5 (left) or MK16-Ras (right) tumour cells into immune-deficient, nude mice (striped bars) or immune-competent, wild-type mice (solid bars). Data represents the fold growth of Sen co-injections over non-Sen co-injections within each mouse strain. * indicates P value <0.05 by Wald test. ns is not significant. Data are presented as mean fold growth+s.e.m. n=6–10 for immune-deficient mice. n=6–19 for immune-competent mice. Senescent cells significantly stimulated tumour growth in wild-type mice but failed to do so in nude mice. (g) Flow cytometry analysis of isografts containing PDSC5 tumour cells and non-Sen or Sen-MSFs. Data represents the mean CD11b⁺Ly6G^Hi cell number per mouse+s.e.m., 4 days following co-injection. * indicates P value <0.05 by Student's t-test. n=4.